Ask AI
ProCE Banner Activity

Are You Achieving “HiSCRs” in Hidradenitis Suppurativa? Expert Guidance for Navigating Diagnosis and Treatment Advancement

Slideset

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease associated with significant burdens, including delayed recognition, diagnostic challenges, and health disparities. This slideset highlights current approaches to early diagnosis and evaluation, evidence for new and emerging HS therapies, and practical strategies for providing individualized, patient-centered care.

Released: July 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Incyte Corporation and Novartis Pharmaceuticals Corporation

Incyte Corporation

Novartis Pharmaceuticals Corporation

Target Audience

This program is intended for dermatologists, dermatology residents and fellows, and other healthcare professionals who care for patients with hidradenitis suppurativa.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize updated diagnostic frameworks to improve early recognition of HS, particularly in high-risk and underserved populations

  • Connect key molecular and cellular drivers of HS to therapeutic targets in approved and investigational treatment strategies

  • Differentiate among available and investigational HS therapies using data-driven insights on outcomes, tolerability, and patient factors

Financial Disclosures

Primary Author

Mickey Horissian, MD, MBA: consultant/advisor/speaker: Regeneron, UCB; researcher: Incyte.

Venessa Peña-Robichaux, MD, has no relevant financial relationships to disclose.